Home
Live Updates
Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B : comparemela.com
Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B
SAN DIEGO--(BUSINESS WIRE)--Dec 10, 2023--
Related Keywords
California ,
United States ,
San Diego ,
American ,
Richard James ,
Joanne Smith Farrell ,
Richard Morgan ,
David Rawlings ,
Richarda Morgan ,
Atlas Venture ,
Us Department Of Health ,
Oral Presentation At American Society Of Hematology ,
American Society Of Hematology ,
Blood Products Advisory Committee ,
Hemophiliab National Bleeding Disorders Foundation ,
Committee On Blood Safety ,
World Federation Of Hemophilia ,
Linkedin ,
Us Centers For Disease ,
Longwood Fund ,
Drug Administration ,
Be Biopharma Inc ,
Seattle Children Research Institute ,
Bristol Myers Squibb ,
Human Services ,
Engineeredb Cell Medicines ,
American Society ,
Chief Scientific Officer ,
Business Wire ,
Glenn Pierce ,
Investigational New Drug ,
Scientific Advisory Board ,
World Federation ,
Vice President Medical ,
States Board ,
Scientific Advisory Council ,
National Bleeding Disorders ,
Blood Safety ,
Sustained Levels ,
Presentation Session ,
Novel Approaches ,
Next Generation Cellular ,
New Class ,
Seattle Children ,
Alta Partners ,
Takeda Ventures ,
Research Institute ,
Disease Control ,
Accessed November ,
Bleeding Disorders ,
Investor Contact ,
Business ,
comparemela.com © 2020. All Rights Reserved.